Buparlisib
- Generic Name
- Buparlisib
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21F3N6O2
- CAS Number
- 944396-07-0
- Unique Ingredient Identifier
- 0ZM2Z182GD
- Background
Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
- Conditions
- Locally Advanced Solid Tumor
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT04975958
- Locations
- 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 483
- Registration Number
- NCT04338399
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- Conditions
- LymphomaMantle Cell LymphomaFollicular LymphomaDiffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02756247
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2019-09-03
- Lead Sponsor
- Emory University
- Target Recruit Count
- 1
- Registration Number
- NCT02614508
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 22
- Registration Number
- NCT02452294
- Locations
- 🇩🇪
Department of Dermatology, University Hospital, Tuebingen, Germany
🇩🇪Department of Dermatology, University Hopsital, Dresden, Germany
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- University Hospital, Essen
- Target Recruit Count
- 48
- Registration Number
- NCT02404844
- Locations
- 🇩🇪
iOMEDICO AG, Freiburg, Baden-Württemberg, Germany
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 14
- Registration Number
- NCT02340780
- Locations
- 🇨🇦
QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦University Health Network, Toronto, Ontario, Canada
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
- Conditions
- Carcinoma, Basal CellRecurrent Skin CancerBasal Cell Nevus SyndromeSkin Neoplasms
- Interventions
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Anne Chang
- Target Recruit Count
- 10
- Registration Number
- NCT02303041
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
- Conditions
- Primary Central Nervous System LymphomaRecurrent/Refractory Secondary Central Nervous System LymphomaLymphoma
- Interventions
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02301364
- Locations
- 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memorial Sloan Kettering West Harrison, Harrison, New York, United States
A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Patrick Joseph Loehrer Sr.
- Target Recruit Count
- 14
- Registration Number
- NCT02220855
- Locations
- 🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.